Elsayed Soliman to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Elsayed Soliman has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
0.373
-
Soliman EZ, Howard G, Judd S, Bhave PD, Howard VJ, Herrington DM. Factors Modifying the Risk of Atrial Fibrillation Associated With Atrial Premature Complexes in Patients With Hypertension. Am J Cardiol. 2020 05 01; 125(9):1324-1331.
Score: 0.153
-
Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011 Jan 05; 12:3.
Score: 0.081
-
Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a Polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med. 2011 Jan; 52(1):10-5.
Score: 0.080
-
Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, Simpson LM, Haywood LJ, Marcus GM. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Circ Arrhythm Electrophysiol. 2017 Dec; 10(12).
Score: 0.033
-
Desai CS, Ning H, Soliman EZ, Burke GL, Shea S, Nazarian S, Lloyd-Jones DM, Greenland P. Electrocardiographic abnormalities and coronary artery calcium for coronary heart disease prediction and reclassification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2014 Sep; 168(3):391-7.
Score: 0.026